On Target

Meet some of the people featured in the July/August 2019 issue of The Scientist.

How we talk about the coming revolution in clinical care matters as much as the need to involve all types of people in the process.

Take a break from the bench to puzzle and peruse.

Selected Images of the Day from the-scientist.com

Scientists are pretty sure they know where the seaweed is coming from. Now they want to know why it’s here.

Sensors encapsulated with oral chemotherapy drugs help patients and physicians keep track of treatments.

The three-dimensional cell cultures are still in the development phase, but researchers are excited about their use to predict patients’ responses to various treatment options.

A six-year study across the Tanzanian mountain’s slopes hints at how land-use practices will interact with a changing climate to influence ecosystems around the world.

A CRISPR-based electronic sensor flags target DNA sequences at high speed.

Researchers use 3-D printing technology to construct a brain cancer model that accurately recapitulated in vivo biology and predicted patient drug responses.

Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.

The expression of a slew of genes in psychiatric patients closely tracks pain intensity and predicts future emergency room visits, according to a study.

By unraveling the molecular underpinnings of inherited blood disorders, the Boston Children’s Hospital researcher has provided the basis for therapies now being tested for beta-thalassemia and sickle cell disease.

The Purdue University nutrition researcher delves into the details of how fat tissue affects tumors.

Researchers are devising ways to prevent viral vectors carrying gene therapies from triggering an immune response.

Insulin-producing cells grown in the lab could offer a functional cure for the disease.

Not only can artificial intelligence revolutionize healthcare, it could help restore the doctor-patient relationship.

Robert Guthrie’s blood test for the metabolic disorder phenylketonuria launched a worldwide movement to screen every baby for the disease soon after birth.

By testing multiple treatments in a single patient, hyperindividualized trial designs could offer more information about treatment efficacy in each participant, and about heterogeneity within and between patients.

See how a computational pipeline uses next-generation sequencing data to identify genetic alterations that produce cancer-specific antigens.

Our resident bacteria can affect the activity of immunotherapies and other medicines in the body.

Researchers combine CRISPR technology with a graphene transistor to create an electronic sensor for particular DNA sequences.

How researchers create a glioblastoma on a chip that can predict patients’ response to treatments

There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.